SYH2069 / CSPC Pharma - LARVOL DELTA

A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin (clinicaltrials.gov) - P2 | N=240 | Not yet recruiting | Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.

Monotherapy • New P2 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and Safety of SYH2069 Injection in Obese Participants Without Diabetes. (clinicaltrials.gov) - P2 | N=360 | Not yet recruiting | Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.

New P2 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • APOB

A Study of SYH2069 Injection in Healthy Participants (clinicaltrials.gov) - P1 | N=104 | Active, not recruiting | Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.

New P1 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

…CSPC Pharmaceutical…is pleased to announce that GLP-1/GIP receptor dual-biased agonist polypeptide injection (SYH2069 Injection) (the 'Product') developed by the Group has obtained approval from the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China (HKEXnews) - "The indication for this clinical trial approval is weight management for individuals with obesity or overweight and at least one weight-related comorbidity."

New trial • Obesity

GLP-1/GIP receptor dual-biased agonist polypeptide injection (SYH2069 injection) obtains clinical trial approval in the U.S. (CSPC Press Release)

IND • Obesity